Consensus guidelines for the timely detection and diagnosis of disease progression in multiple sclerosis patients

Celia Oreja-Guevara¹, Bonaventura Casanova², Antonio García-Merino³, Lucienne Costa-Frossard⁴, Dionisio Fernández-Uría⁵, José Ramón Ara⁶, José María Prieto⁷, Carmen Calles⁸, Miguel Ángel Hernández⁹, Jordi Río¹⁰, Carmen Durán¹¹, Guillermo Izquierdo¹², Sara Eichau¹³, Alfredo Rodríguez-Antigüedad¹⁴, María José Moreno¹⁵, David Fernández¹⁵, José E. Meca-Lallana¹⁶

Poster Session: P0248

 \mathbf{x}

 \mathbf{x}

YYJYYJYYY JYYJYYJYY LYYJYYJYY YYJYYJYYY YYJYYJYY

イントインイン

777777777777

 \mathbf{x}

 \mathbf{x}

 \mathbf{X}

¹Hospital Universitario Clínico San Carlos, Madrid, Spain; ²Hospital Universitario y Politécnico La Fe, Valencia, Spain; ³Hospital Universitario Puerta de Hierro, Madrid, Spain; ⁴Hospital Universitario Ramón y Cajal, Madrid, Spain; ⁵Hospital Universitario de Cabueñes, Gijón, Spain; ⁶Hospital Universitario Miguel Servet, Zaragoza, Spain; ⁷Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain; ⁸Hospital Universitario Son Espases, Palma de Mallorca, Spain; ⁹Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain; ¹⁰CEMCAT, Hospital Universitario Vall d'Hebrón, Barcelona, Spain; ¹¹Hospital Universitario de Badajoz, Madrid, Spain; ¹²Fundación DINAC, Sevilla, Spain; ¹³Hospital Universitario Virgen Macarena, Sevilla, Spain; ¹⁴Hospital de Cruces, Barakaldo, Bizkaia, Spain; ¹⁵Novartis Farmacéutica, Barcelona, Spain; ¹⁶Hospital Clínico Universitario Virgen de la Arrixaca (IMIB-ARRIXACA), Murcia, Spain

Poster Presentation at the 8th Joint ACTRIMS-ECTRIMS Meeting, MSVirtual 2020, September 11–13, 2020



Scan to download a copy of this presentation

http://www.medcommshydhosting.co m/Neuroscience/MS/index.htm

Copyright © 2020 Novartis Pharma AG. All rights reserved

Disclosures

Celia Oreja-Guevara C. has received honoraria for speaking and/or consultancy from Biogen, Sanofi-Genzyme, Merck, Roche, Teva, and Novartis

Bonaventura Casanova has received research support or personal compensation from any commercial entity (for-profit business) for employment, consulting, serving on a scientific advisory board, speaking, or other activities from BIOGEN; SANOFI; ROCHE; MERCK; TEVA; NOVARTIS; CELGENE; ALMIRALL.

Antonio García-Merino has received compensation for lecturing, scientific advisory board and consulting from Novartis, Merck, Roche, Emerald, Biogen and Sanofi and research support from Teva.

Lucienne Costa-Frossard has received honoraria for speaking, consultancy, clinical research and mobility from Merck, Bayer, Biogen, Novartis, Sanofi-Genzyme, Almirall, Roche, Celgene, Biopas, Ipsen and Teva

Dionisio Fernández-Uría has received personal compensation for speaking, formation, advisory or clinical trials from HBiogen, Merck, Novartis, Roche, Sanofi, Teva, Bayer and Almirall

José Ramón Ara has received honoraria for lecturing, travel expenses for attending meetings, or financial support for research from Biogen Idec, Merck Serono, Genzyme and Novartis

José María Prieto is a consultant for Bayer HealthCare Pharmaceuticals, Biogen Idec Inc., Genzyme Corporation, Merck Serono, Novartis Pharmaceuticals Corporation, Sanofi-Aventis, Teva Pharmaceuticals, Roche Pharma and Almirall Prodesfarma S.A. He has participated as a speaker/moderator in meetings and/or symposia organized by Almirall Prodesfarma S.A., Bayer HealthCare Pharmaceuticals, Biogen Idec Inc, Genzyme Corporation, Merck Serono, Novartis Pharmaceuticals Corporation, Sanofi-Aventis, Teva Pharmaceuticals and Roche. He has received grants for research projects from Almirall Prodesfarma S.A., Biogen Idec, Novartis Pharmaceuticals Corporation and Sanofi Genzyme S.A.

Carmen Calles has received personal compensation from any commercial entity (for-profit business) for employment, consulting, serving on a scientific advisory board, speaking, or other activities from Teva, Sanofi-Genzyme, Merck, Novartis, Biogen, Roche

Miguel Ángel Hernández has received research support or personal compensation from any commercial entity (for-profit business) for employment, consulting, serving on a scientific advisory board, speaking, or other activities from Biogen, Novartis, Roche, Merck, Teva, Genzyme-Sanofi.

Jordi Río has received speaking honoraria and personal compensation for participating on Advisory Boards from Biogen-Idec, Genzyme, Merck- Serono, Novartis, Teva, and Sanofi-Aventis.

Carmen Durán has received speaking and/or advisory board honoraria from: Sanofi, Novartis, AbbVie and Bial

Guillermo Izquierdo has received speaking and/or advisory board honoraria from: Sanofi, Novartis, AbbVie and Bial

Sara Eichau received speaker honoraria and consultant fees from Biogen, Novartis, Sanofi Genzyme, Merck, Almirall, Roche and Teva.

Alfredo Rodríguez-Antigüedad has received personal compensation from any commercial entity (for-profit business) for employment, consulting, serving on a scientific advisory board, speaking, or other activities from Merck, Biogen idec, Roche, Genzyme, Teva, Myland, Celgene

María José Moreno and David Fernández are employees of Novartis Farmacéutica

José E. Meca-Lallana has received grants and consulting or speaking fees from Almirall, Biogen, Celgene, Genzyme, Merck, Novartis, Roche and Teva.

The study was funded by Novartis Farmacéutica S.A., Spain. Medical writing support was provided by María Yuste. The final responsibility for the content lies with the authors.

Background and objective

- Secondary Progressive Multiple Sclerosis (SPMS) is a clinical form of MS characterized by gradual accrual of disability independent of relapses over time¹
- Consensus guidelines for the timely detection and management of SPMS are **limited**²
- As a consequence, SPMS is frequently diagnosed retrospectively², potentially reducing treatment impact

Objective

To establish consensus on patient monitorization and on the most relevant clinical variables for early identification of disease progression in MS


Methods

A two-round RAND-UCLA method was used, involving a panel of **15 MS** specialists in Spain

Consensus questionnaire characteristics

- Level of **agreement**:
 - Items were rated on a 4-point Likert scale _
 - Consensus was defined as \geq 66% agreement _ (sum of 3 and 4 scores) for each question





- Round 1: 72 open-ended questions
- Round 2: 11 additional questions were included based on panel feedback in Round 1
- **3 dimensions:** Clinical (Monitoring and EDSS, Cognitive exploration, Other evaluations), Radiological and Biomarker detection

1	2	3	4
Totally disagree	Disagree	Agree	Totally agree

Monitoring and EDSS

Progression definition

88

Minimum time to confirm disability progression

Longer disease duration and age are not confirmatory of disease progression per se.

				Level of agreement
DSS is the best varia	ble to define p	orogression		93%
Progression could be d baseline is ≤ 5.5 or 0.5 Considering a minimum confirmation of progres	points if the E n EDSS of 4, a	DSS baseline pyramidal fund	score is ≥ 6 . ction system of	100%
	3 months	6 months	12 months	
Level of agreement (%)	Agree 73%*	Agree 87%	Disagree 73%	Potential exceptions: *patients clinically and/or radiologically unstable in relation with DMT and patients with non-confirmatory signs of progression. Patients with suspected progression (every 3 months)
				Level of agreement
20% time increase in 3 9HPT, with an increas			in	87%

Confirmatory variables of progression

Cognitive and other explorations

- \bigtriangledown
- To perform an **annual** cognitive exploration such as SDMT, BRB-N or BICAMS
- \bigcirc
- To evaluate once annually with scales:
- Quality of Life (QoL)
- Depression
- Fatigue
- **Spasticity** (if there is an alteration on the piramidal system)

Radiological identification

A sustained **change in** both **brain and medullary atrophy suggests progression** but **more precise techniques** should be used to confirm a **diagnosis**

- Patients should be proactively asked about their symptoms and impairment, as it allows for **suspected progression**
- BICAMS and BRB-N can be performed by a qualified team member when a neuropsychologist is not available
- A complete neuropsychological study should be performed when progression is suspected

- Main biomarkers to detect progression:
 - Presence of ectopic lymphoid follicles in the meninges of patients
 - Quantification of Neurofilament Light Chain in blood
 - Optical coherence tomography (OCT) test

 $(\checkmark$

Variables of suspected progression



	Level of agreement
Worsening of 2-points in any functional system	80%
• Worsening of 2-points in functional system, < 10 years of disease	93%
Worsening of 2-points in functional system , 10-20 years of disease	87%
 Worsening of 2-points in functional system , < 35 years of disease 	73%
Worsening of 2-points in functional system , 35-45 years of disease	87%
 >20% time increase in T25-FW 	93%
 > 20% time increase in 9HPT 	87%
 >20% time increase in T25-FW + >20% time increase in 9-HPT 	100%
 > 20% in 2 minutes walk test 	87%
Repeated falls to the floor	100%
• < 20% in SDMT	93%
Worsening 20% in 2 battery sub-test	87%
Worsening 20% in 2 battery sub-test	87%
Cognitive function worsening	87%
Change in brain atrophy degree	80%
Diffuse hyperintensity / confluent lesions	80%
Lymphoid follicles	67%

Variables NOT confirmatory of progression $\frac{8}{28}$

	Variables	Level of agreement
Functional assessment and EDSS Cognitive exploration	Worsening of 2-points in any functional system	67%
	 Worsening of 2-points in functional system , < 10 years of disease 	67%
	 >20% time increase in T25-FW 	93%
	 >20% time increase in 9-HPT 	100%
	 > 20% in 2 minutes walk test 	93%
	Repeated falls to the floor	93%
	• < 20% in SDMT	93%
	Worsening 20% in 2 battery sub-test	80%
	Worsening 20% in 2 battery sub-test	77%

EDSS, Expanded Disability Status Scale; SDMT, Symbol Digit Modalities Test; T25-FW, Timed 25-Foot Walk; 9HPT, 9-Hole Peg Test

Variables that need more precise techniques to confirm a diagnosis



	Variables	Level of agreement
Functional assessment and EDSS	 Worsening of 2-points in any functional system 	67%
	 Worsening of 2-points in functional system , < 10 years of disease 	67%
	 > 20% time increase in T25-FW 	93%
	 >20% time increase in 9-HPT 	100%
	 > 20% in 2 minutes walk test 	93 %
Cognitive exploration	Repeated falls to the floor	93 %
	• < 20% in SDMT	93 %
	 Worsening 20% in 2 battery sub-test 	80%
	 Worsening 20% in 2 battery sub-test 	77%
Radiological detection	Sustained medullary atrophy	93%

Conclusions

- The expert panel agreed that EDSS is the best variable to define progression in MS. Increase in EDSS together with a 20% time increase in 25FT-WT and 9-HPT is confirmatory of disease progression.
- Monitorization of cognitive status, QoL and patient reported outcomes and anamnesis can guide the early detection of disease progression
- With a consensus agreed on 73 of a total of 83 questions (87.6%), these areas of collective agreement could guide neurologists in anticipating progression and planning informed clinical and therapeutic interventions

Thank you

 \mathbf{x} \mathbf{x} **YXXYXXXXX** \mathbf{x} \mathbf{x}

XXXXXXXXXX \mathbf{x} \mathbf{x} \mathbf{x} \mathbf{x} \mathbf{x} \mathbf{x} \mathbf{x} \mathbf{x} YYYYYYYYYY \mathbf{x} **XXXXXXXXXX** \mathbf{x} **XXXXXXXXXX**